ESLA insider buying and SEC filings, explained
Estrella Immunopharma, Inc. · CIK 1844417
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq, Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- Fiscal year end
- Dec 31
- Former names
- TradeUP Acquisition Corp.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 11–Oct 7, 2025 | Purchase (code P) | Jiandong Xu (CFO) bought 2,100 shares directly and indirectly (by spouse) between Sep 11, 2025 and Oct 7, 2025 at about $1.24 ($3K), reported as a purchase (code P). Direct holdings up <1% to 265,488 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 29, 2026 |
2 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Oct 29, 2026, 5:28 PM ET 8-K | Executive or director change (Item 5.02) Other event (Item 8.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ESLA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.